However, current score systems actually recommended by guidelines for assessing CVD risk in asymptomatic adults (e.g., Framingham Risk Score, European SCORE-2 and SCORE-2 OP, the ASCVD score), although based on the identification of several risk factors, may fail to correctly identify NAFLD-related CVD because parameters such as insulin resistance are not included in their calculation [25]. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.